Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Doravirine/Islatravir in Virologically Suppressed HIV-1 Patients
2019-000586-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doravirine + islatravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 and Antiretroviral activity at Week 48. Started Nov 2019; status: completed.
02
Drugs
doravirine + islatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-000586-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000586-20.